Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
Views & Analysis A new age: the real-world development pathway Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
News FDA and EMA to work more closely on paediatric drug regulati... FDA and EMA hope to streamline development of paediatric plans.
Views & Analysis Could the EMA really stay in London? After the UK voted to leave Europe, its seems obvious that the European Medicines Agency will have to leave London - but GSK’s Andrew Witty and others hope it might stay.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
